Blood Pressure Control in Patients with Diabetic Kidney Disease

Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yaeni, Kim, Won, Kim, Jwa-Kyung, Moon, Ju Young, Park, Samel, Park, Cheol Whee, Park, Hoon Suk, Song, Sang Heon, Yoo, Tae-Hyun, Lee, So-Young, Lee, Eun Young, Lee, Jeonghwan, Jin, Kyubok, Cha, Dae Ryong, Cha, Jin Joo, Han, Sang Youb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Electrolyte Metabolism 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827046/
https://www.ncbi.nlm.nih.gov/pubmed/36688208
http://dx.doi.org/10.5049/EBP.2022.20.2.39
Descripción
Sumario:Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.

Ejemplares similares